BR112015000275A2 - utilização de um extrato de mirta como agente anti-biopelícula face p. acnes - Google Patents

utilização de um extrato de mirta como agente anti-biopelícula face p. acnes

Info

Publication number
BR112015000275A2
BR112015000275A2 BR112015000275A BR112015000275A BR112015000275A2 BR 112015000275 A2 BR112015000275 A2 BR 112015000275A2 BR 112015000275 A BR112015000275 A BR 112015000275A BR 112015000275 A BR112015000275 A BR 112015000275A BR 112015000275 A2 BR112015000275 A2 BR 112015000275A2
Authority
BR
Brazil
Prior art keywords
acnes
myrtle extract
biofilm agent
biofilm
myrtle
Prior art date
Application number
BR112015000275A
Other languages
English (en)
Other versions
BR112015000275B1 (pt
Inventor
Fiorini-Puybaret Christel
Luc Joelle
Original Assignee
Fabre Pierre Dermo Cosmetique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fabre Pierre Dermo Cosmetique filed Critical Fabre Pierre Dermo Cosmetique
Publication of BR112015000275A2 publication Critical patent/BR112015000275A2/pt
Publication of BR112015000275B1 publication Critical patent/BR112015000275B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Abstract

resumo patente de invenção: "utilização de um extrato de mirta como agente anti-biopelícula face a p.acnes". a presente invenção refere-se a uma composição dermatológica contendo um extrato de mirta a uma concentração superior ou igual a 0,01 % em peso, para sua utilização como agente anti-biopelícula face o propionibacterium acnes.
BR112015000275-7A 2012-07-09 2013-07-08 composição dermatológica, produto de combinação de composição dermatológica, uso de extrato de murta e composição contendo o referido extrato BR112015000275B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1256607A FR2992862B1 (fr) 2012-07-09 2012-07-09 Utilisation d'un extrait de myrte en tant qu'agent anti-biofilm vis-a-vis de p. acnes
FR1256607 2012-07-09
PCT/EP2013/064415 WO2014009325A1 (fr) 2012-07-09 2013-07-08 Utilisation d'un extrait de myrte en tant qu'agent anti-biofilm vis-a-vis de p. acnes

Publications (2)

Publication Number Publication Date
BR112015000275A2 true BR112015000275A2 (pt) 2017-06-27
BR112015000275B1 BR112015000275B1 (pt) 2021-02-09

Family

ID=47022816

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015000275-7A BR112015000275B1 (pt) 2012-07-09 2013-07-08 composição dermatológica, produto de combinação de composição dermatológica, uso de extrato de murta e composição contendo o referido extrato

Country Status (9)

Country Link
US (1) US9808496B2 (pt)
EP (1) EP2869827B1 (pt)
JP (1) JP2015522054A (pt)
BR (1) BR112015000275B1 (pt)
CA (1) CA2878496C (pt)
ES (1) ES2635382T3 (pt)
FR (1) FR2992862B1 (pt)
MX (1) MX355668B (pt)
WO (1) WO2014009325A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE112008001301T5 (de) 2007-05-14 2010-04-29 Reserach Foundation Of State University Of New York Induktion einer physiologischen Dispersions-Antwort in Bakterien-Zellen in einem Biofilm
GB2565511B (en) 2016-05-26 2022-04-13 Kimberly Clark Co Anti-adherent compositions and methods of inhibiting the adherence of microbes to a surface
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
FR3120790B1 (fr) 2021-03-10 2024-03-15 Fabre Pierre Dermo Cosmetique Association d’un extrait de myrte et d’un extrait de Tripterygium wilfordii pour lutter contre l’inflammation induite par C. acnes
FR3132632A1 (fr) 2022-02-17 2023-08-18 Pierre Fabre Dermo-Cosmetique Composition comprenant un extrait de myrte et un extrait de Tripterygium wilfordii pour lutter contre l’acné des zones non lésionnelles de la peau acnéique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2783425B1 (fr) 1998-09-17 2002-06-07 Fabre Pierre Dermo Cosmetique Extrait de myrte titre en myrtucommulone b', son procede de preparation et son application en dermatologie et en cosmetologie
US20060008538A1 (en) * 2004-07-07 2006-01-12 Wu Jeffrey M Methods of treating the skin
US9254257B2 (en) * 2010-10-21 2016-02-09 Cadila Healthcare Limited Method for treatment of acne using pharmaceutical compositions of clindamycin

Also Published As

Publication number Publication date
EP2869827A1 (fr) 2015-05-13
CA2878496A1 (fr) 2014-01-16
FR2992862B1 (fr) 2014-10-03
BR112015000275B1 (pt) 2021-02-09
WO2014009325A1 (fr) 2014-01-16
CA2878496C (fr) 2020-12-15
MX2015000276A (es) 2015-07-21
JP2015522054A (ja) 2015-08-03
MX355668B (es) 2018-04-24
FR2992862A1 (fr) 2014-01-10
US20150190447A1 (en) 2015-07-09
ES2635382T3 (es) 2017-10-03
EP2869827B1 (fr) 2017-05-03
US9808496B2 (en) 2017-11-07

Similar Documents

Publication Publication Date Title
BR112014017749A8 (pt) Composto alquinilbenzeno 3,5-dissubstituído e sal do mesmo
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
PH12016501151A1 (en) Nrf2 regulators
BR112015022417A2 (pt) métodos e composições para inibição de proteínas contendo bromodomínio
BR112015022047A8 (pt) uso de uma composição compreendendo nanopartículas contendo um fármaco da família limo e uma albumina
PH12015500825B1 (en) Substituted benzene compounds
BR112015001618A2 (pt) composições fungicidas
CL2017002082A1 (es) Nuevas proteínas especificas para pioverdina y pioquelina
BR112015022972A2 (pt) composição farmacêutica de cloridrato de s-cetamina
BR112016013299A2 (pt) Composto
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
BR112019024785A2 (pt) composto de bifenila ou sal do mesmo, composição farmacêutica, agente antineoplásico e uso
BR112016022593A2 (pt) composições e métodos para modular a expressão do fator b do complemento
BR112015009989A2 (pt) estabilizante para a hialuronidase e formulação líquida que compreende hialuronidase
BR112015011430A2 (pt) composição para liberação imediata e prolongada
BR112016007068A2 (pt) ?composições cosméticas?
MX2013002948A (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
BR112015022092A2 (pt) derivado de di-hidropiridazina-3,5-diona
BR112015000275A2 (pt) utilização de um extrato de mirta como agente anti-biopelícula face p. acnes
BR112015015515A2 (pt) composições fungicidas sinérgicas
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
CL2014002845A1 (es) Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B06I Technical and formal requirements: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa)

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B09A Decision: intention to grant
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/07/2013, OBSERVADAS AS CONDICOES LEGAIS.